After a Ph.D in T cell biology, I chose to move my research closer to the patient bedside and studied the mechanism of action of anti-tumor immunotherapies. My work focused on cellular therapies such as CAR T cells and tumor-targeting antibodies that can trigger phagocytosis of tumor cells. I am now leading a new line of research within the team of Philippe Bousso about CAR-expressing macrophages that are receiving increasing interest for the treatment of solid cancers, that are the most majority of cancer type. My team includes a Ph.D student and an engineer.
